Insights - After a much-needed meeting between pharmaceutical representatives and Donald Trump this morning, biopharma stocks are rallying. To summarize, Trump’s comments after the meeting (a 10-minute … Continue Reading
Read nowInsights - In case you haven’t already seen the quotes, Donald Trump took aim at the pharmaceutical industry in a press conference this afternoon, sending bio/pharma stocks … Continue Reading
Read nowResearch - Sarepta Therapeutics (SRPT) is presenting at the JPMorgan Healthcare Conference right now, and released the first figures from the launch of Exondys 51. 250 patients … Continue Reading
PremiumResearch - Revance Therapeutics (RVNC) just doesn’t stop. After hours on Thursday the company issued a 2017 update. Though we note nothing critical here, the company now … Continue Reading
PremiumInsights - U.S. equities continue to sit at all-time highs, with financials, transportation, and energy leading the way, while biotech lags. The under-performance isn’t just from biotech/drug … Continue Reading
Read nowInsights - Revance Therapeutics’ (RVNC) cervical dystonia results were released after the bell on Monday. The phase 2 trial was an open-label dose-ranging study to evaluate the … Continue Reading
PremiumInsights - Biotech stocks are getting shellacked today due to a Trump comment in Time’s “Person of the Year” edition. It’s quite literally a single comment on … Continue Reading
Read now
